Drug Profile
Research programme: heat shock transcription factor stimulants - Chaperone Pharma
Alternative Names: NYK 1112; NYK 1341; NYK-1005; NYK-1007Latest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator Nyken
- Developer Chaperone Pharma
- Class
- Mechanism of Action Heat shock transcription factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute kidney injury; Atrial fibrillation; Delayed graft function; Heart failure
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for preclinical development in Acute kidney injury in Netherlands (IV)
- 28 Jun 2020 No recent reports of development identified for preclinical development in Delayed-graft-function in Netherlands (IV)
- 28 Jun 2020 No recent reports of development identified for research development in Heart-failure in Netherlands (PO)